Synthesis, structure-activity relationship studies, and antibacterial evaluation of 4-chromanones and chalcones, as well as olympicin A and derivatives

Journal of Medicinal Chemistry

Volumn 57, Issue 20, 2014, Pages 8398-8420

  Feng, Li ^a   Maddox, Marcus M ^b   Alam, Md Zahidul ^c   Tsutsumi, Lissa S ^a   Narula, Gagandeep ^d   Bruhn, David F ^b   Wu, Xiaoqian ^c   Sandhaus, Shayna ^d   Lee, Robin B ^b   Simmons, Charles J ^a   Tse Dinh, Yuk Ching ^d   Hurdle, Julian G ^c   Lee, Richard E ^b   Sun, Dianqing ^a  

^a UNIVERSITY OF HAWAII AT HILO   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS AT ARLINGTON   (United States)

^d FLORIDA INTERNATIONAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DIHYDROXYPHENYL) 3 (6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YL)PROP 2 EN 1 ONE; 2 (2,6 DIMETHYLHEPT 5 EN 1 YL) 5 HYDROXYCHROMAN 4 ONE; 2 (2,6 DIMETHYLHEPT 5 EN 1 YL) 6 HYDROXYCHROMAN 4 ONE; 2 (2,6 DIMETHYLHEPT 5 EN 1 YL) 7 HYDROXYCHROMAN 4 ONE; 2 (6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YL) 7 (METHOXYMETHOXY)CHROMAN 4 ONE; 2 (6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YL) 7 HYDROXYCHROMAN 4 ONE; 2 HEPTYL 7 HYDROXYCHROMAN 4 ONE; 2 HEPTYLCHROMAN 4,7 DIOL; 2 HEXYL 7 HYDROXYCHROMAN 4 ONE; 2 HEXYLCHROMAN 4,7 DIOL; 2 NONYLCHROMAN 4,7 DIOL; 2 PROPYLCHROMAN 4,7 DIOL; 3 (6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YL) 1 [2 HYDROXY 4 (METHOXYMETHOXY)PHENYL]PROP 2 EN 1 ONE; 4 CHROMANONE DERIVATIVE; 5,7 BIS(METHOXYMETHOXY) 2 PROPYLCHROMAN 4 ONE; 7 HYDROXY 2 NONYLCHROMAN 4 ONE; 7 HYDROXY 2 PHENETHYLCHROMAN 4 ONE; 7 HYDROXY 2 PROPYLCHROMAN 4 ONE; ANTIINFECTIVE AGENT; CHALCONE DERIVATIVE; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; ERYTHROMYCIN; FLAVONOID; ISONIAZID; OLYMPICIN A; OLYMPICIN A DERIVATIVE; RIFAMPICIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; 4-CHROMANONE; CHROMONE DERIVATIVE; GYRASE INHIBITOR; PHLOROGLUCINOL;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL MEMBRANE; CYTOTOXICITY; DRUG MECHANISM; DRUG SOLUBILITY; DRUG SYNTHESIS; ENTEROCOCCUS FAECALIS; ENZYME INHIBITION; ESCHERICHIA COLI; HYDROGEN BOND; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; STAPHYLOCOCCUS AUREUS; STRUCTURE ACTIVITY RELATION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CHLOROCEBUS AETHIOPS; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; SYNTHESIS; VERO CELL LINE;

ANIMALS; ANTI-BACTERIAL AGENTS; CERCOPITHECUS AETHIOPS; CHALCONES; CHEMISTRY TECHNIQUES, SYNTHETIC; CHROMONES; DNA GYRASE; DNA TOPOISOMERASE IV; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; PHLOROGLUCINOL; STRUCTURE-ACTIVITY RELATIONSHIP; TOPOISOMERASE II INHIBITORS; VERO CELLS;

EID: 84908384003     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500853v     Document Type: Article

References (79)

1. Cushnie, T. P. T.; Lamb, A. J. Antimicrobial activity of flavonoids Int. J. Antimicrob. Agents 2005, 26, 343-356
2. Gutierrez-Lugo, M.-T.; Bewley, C. A. Natural products, small molecules, and genetics in tuberculosis drug development J. Med. Chem. 2008, 51, 2606-2612
3. Negi, A. S.; Kumar, J. K.; Luqman, S.; Saikia, D.; Khanuja, S. P. S. Antitubercular potential of plants: a brief account of some important molecules Med. Res. Rev. 2010, 30, 603-645
4. Walsh, C. Where will new antibiotics come from? Nat. Rev. Microbiol. 2003, 1, 65-70
5. Shang, S.; Tan, D. S. Advancing chemistry and biology through diversity-oriented synthesis of natural product-like libraries Curr. Opin. Chem. Biol. 2005, 9, 248-258
6. Havsteen, B. Flavonoids, a class of natural products of high pharmacological potency Biochem. Pharmacol. 1983, 32, 1141-1148
7. Harborne, J. B.; Williams, C. A. Advances in flavonoid research since 1992 Phytochemistry 2000, 55, 481-504
8. Middleton, E., Jr.; Kandaswami, C.; Theoharides, T. C. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer Pharmacol. Rev. 2000, 52, 673-751
9. Knekt, P.; Jarvinen, R.; Seppanen, R.; Heliovaara, M.; Teppo, L.; Pukkala, E.; Aromaa, A. Dietary flavonoids and the risk of lung cancer and other malignant neoplasms Am. J. Epidemiol. 1997, 146, 223-230
10. Knekt, P.; Kumpulainen, J.; Jarvinen, R.; Rissanen, H.; Heliovaara, M.; Reunanen, A.; Hakulinen, T.; Aromaa, A. Flavonoid intake and risk of chronic diseases Am. J. Clin. Nutr. 2002, 76, 560-568
11. Le Marchand, L.; Murphy, S. P.; Hankin, J. H.; Wilkens, L. R.; Kolonel, L. N. Intake of flavonoids and lung cancer J. Natl. Cancer Inst. 2000, 92, 154-160
12. Wang, Y.; Stevens, V. L.; Shah, R.; Peterson, J. J.; Dwyer, J. T.; Gapstur, S. M.; McCullough, M. L. Dietary flavonoid and proanthocyanidin intakes and prostate cancer risk in a prospective cohort of US men Am. J. Epidemiol. 2014, 179, 974-986
13. Andrews, L. Dietary flavonoids for the prevention of colorectal cancer Clin. J. Oncol. Nurs. 2013, 17, 671-672
14. Gradisar, H.; Pristovsek, P.; Plaper, A.; Jerala, R. Green tea catechins inhibit bacterial DNA gyrase by interaction with its ATP binding site J. Med. Chem. 2006, 50, 264-271
15. Favela-Hernández, J. M. J.; García, A.; Garza-González, E.; Rivas-Galindo, V. M.; Camacho-Corona, M. R. Antibacterial and antimycobacterial lignans and flavonoids from Larrea tridentata Phytother. Res. 2012, 26, 1957-1960
16. Cushnie, T. P. T.; Lamb, A. J. Recent advances in understanding the antibacterial properties of flavonoids Int. J. Antimicrob. Agents 2011, 38, 99-107
17. Ballesteros, J. F.; Sanz, M. J.; Ubeda, A.; Miranda, M. A.; Iborra, S.; Paya, M.; Alcaraz, M. J. Synthesis and pharmacological evaluation of 2′-hydroxychalcones and flavones as inhibitors of inflammatory mediators generation J. Med. Chem. 1995, 38, 2794-2797
18. Wu, J.; Li, J.; Cai, Y.; Pan, Y.; Ye, F.; Zhang, Y.; Zhao, Y.; Yang, S.; Li, X.; Liang, G. Evaluation and discovery of novel synthetic chalcone derivatives as anti-inflammatory agents J. Med. Chem. 2011, 54, 8110-8123
19. Takemura, H.; Sakakibara, H.; Yamazaki, S.; Shimoi, K. Breast cancer and flavonoids-a role in prevention Curr. Pharm. Des. 2013, 19, 6125-6132
20. Park, E. J.; Pezzuto, J. M. Flavonoids in cancer prevention Anti-Cancer Agents Med. Chem. 2012, 12, 836-851
21. Echeverria, C.; Santibanez, J. F.; Donoso-Tauda, O.; Escobar, C.; Ramirez-Tagle, R. Structural antitumoral activity relationships of synthetic chalcones Int. J. Mol. Sci. 2009, 10, 221-231
22. Loa, J.; Chow, P.; Zhang, K. Studies of structure-activity relationship on plant polyphenol-induced suppression of human liver cancer cells Cancer Chemother. Pharmacol. 2009, 63, 1007-1016
23. Stevenson, D.; Hurst, R. Polyphenolic phytochemicals-just antioxidants or much more? Cell. Mol. Life Sci. 2007, 64, 2900-2916
24. Erasto, P.; Bojase-Moleta, G.; Majinda, R. R. T. Antimicrobial and antioxidant flavonoids from the root wood of Bolusanthus speciosus Phytochemistry 2004, 65, 875-880
25. Weiss, R. B.; Greene, R. F.; Knight, R. D.; Collins, J. M.; Pelosi, J. J.; Sulkes, A.; Curt, G. A. Phase I and clinical pharmacology study of intravenous flavone acetic acid (NSC 347512) Cancer Res. 1988, 48, 5878-5882
26. Senderowicz, A. M. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials Invest. New Drugs 1999, 17, 313-320
27. Burdette-Radoux, S.; Tozer, R. G.; Lohmann, R. C.; Quirt, I.; Ernst, D. S.; Walsh, W.; Wainman, N.; Colevas, A. D.; Eisenhauer, E. A. Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma Invest. New Drugs 2004, 22, 315-322
28. Jones, J. A.; Rupert, A. S.; Poi, M.; Phelps, M. A.; Andritsos, L.; Baiocchi, R.; Benson, D. M.; Blum, K. A.; Christian, B.; Flynn, J.; Penza, S.; Porcu, P.; Grever, M. R.; Byrd, J. C. Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma Am. J. Hematol. 2014, 89, 19-24
29. Loguercio, C.; Festi, D. Silybin and the liver: from basic research to clinical practice World J. Gastroenterol. 2011, 17, 2288-2301
30. Cheung, C. W. Y.; Gibbons, N.; Johnson, D. W.; Nicol, D. L. Silibinin-a promising new treatment for cancer Anti-Cancer Agents Med. Chem. 2010, 10, 186-195
31. Ferry, D. R.; Smith, A.; Malkhandi, J.; Fyfe, D. W.; deTakats, P. G.; Anderson, D.; Baker, J.; Kerr, D. J. Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition Clin. Cancer Res. 1996, 2, 659-668
32. Mulholland, P. J.; Ferry, D. R.; Anderson, D.; Hussain, S. A.; Young, A. M.; Cook, J. E.; Hodgkin, E.; Seymour, L. W.; Kerr, D. J. Pre-clinical and clinical study of QC12, a water-soluble, pro-drug of quercetin Ann. Oncol. 2001, 12, 245-248
33. Bast, A.; Haenen, G.; Bruynzeel, A.; Van der Vijgh, W. Protection by flavonoids against anthracycline cardiotoxicity: from chemistry to clinical trials Cardiovasc. Toxicol. 2007, 7, 154-159
34. Savoia, D. Plant-derived antimicrobial compounds: alternatives to antibiotics Future Microbiol. 2012, 7, 979-990
35. Jandial, D. D.; Blair, C. A.; Zhang, S.; Krill, L. S.; Zhang, Y. B.; Zi, X. Molecular targeted approaches to cancer therapy and prevention using chalcones Curr. Cancer Drug Targets 2014, 14, 181-200
36. Kumar, D.; Kumar, M.; Kumar, A.; Singh, S. K. Chalcone and curcumin derivatives: a way ahead for malarial treatment Mini-Rev. Med. Chem. 2013, 13, 2116-2133
37. Bukhari, S. N. A.; Franzblau, S. G.; Jantan, I.; Jasamai, M. Current prospects of synthetic curcumin analogs and chalcone derivatives against Mycobacterium tuberculosis Med. Chem. 2013, 9, 897-903
38. Lin, Y.-M.; Zhou, Y.; Flavin, M. T.; Zhou, L.-M.; Nie, W.; Chen, F.-C. Chalcones and flavonoids as anti-tuberculosis agents Bioorg. Med. Chem. 2002, 10, 2795-2802
39. Cabrera, M.; Simoens, M.; Falchi, G.; Lavaggi, M. L.; Piro, O. E.; Castellano, E. E.; Vidal, A.; Azqueta, A.; Monge, A.; de Ceráin, A. L.; Sagrera, G.; Seoane, G.; Cerecetto, H.; González, M. Synthetic chalcones, flavanones, and flavones as antitumoral agents: Biological evaluation and structure-activity relationships Bioorg. Med. Chem. 2007, 15, 3356-3367
40. Chiari, M. E.; Vera, D. M. A.; Palacios, S. M.; Carpinella, M. C. Tyrosinase inhibitory activity of a 6-isoprenoid-substituted flavanone isolated from Dalea elegans Bioorg. Med. Chem. 2011, 19, 3474-3482
41. Tsuchiya, H.; Sato, M.; Miyazaki, T.; Fujiwara, S.; Tanigaki, S.; Ohyama, M.; Tanaka, T.; Iinuma, M. Comparative study on the antibacterial activity of phytochemical flavanones against methicillin-resistant Staphylococcus aureus J. Ethnopharmacol. 1996, 50, 27-34
42. Pouget, C.; Fagnere, C.; Basly, J.-P.; Besson, A.-E.; Champavier, Y.; Habrioux, G.; Chulia, A.-J. Synthesis and aromatase inhibitory activity of flavanones Pharm. Res. 2002, 19, 286-291
43. Sun, D.; Hurdle, J. G.; Lee, R.; Lee, R.; Cushman, M.; Pezzuto, J. M. Evaluation of flavonoid and resveratrol chemical libraries reveals abyssinone II as a promising antibacterial lead ChemMedChem 2012, 7, 1541-1545
44. Shiu, W. K. P.; Rahman, M. M.; Curry, J.; Stapleton, P.; Zloh, M.; Malkinson, J. P.; Gibbons, S. Antibacterial acylphloroglucinols from Hypericum olympicum J. Nat. Prod. 2012, 75, 336-343
45. Shiu, W. K. P.; Malkinson, J. P.; Rahman, M. M.; Curry, J.; Stapleton, P.; Gunaratnam, M.; Neidle, S.; Mushtaq, S.; Warner, M.; Livermore, D. M.; Evangelopoulos, D.; Basavannacharya, C.; Bhakta, S.; Schindler, B. D.; Seo, S. M.; Coleman, D.; Kaatz, G. W.; Gibbons, S. A new plant-derived antibacterial is an inhibitor of efflux pumps in Staphylococcus aureus Int. J. Antimicrob. Agents 2013, 42, 513-518
46. Wu, X.; Alam, M. Z.; Feng, L.; Tsutsumi, L. S.; Sun, D.; Hurdle, J. G. Prospects for flavonoid and related phytochemicals as nature-inspired treatments for Clostridium difficile infection J. Appl. Microbiol. 2014, 116, 23-31
47. Simon, O.; Reux, B.; La Clair, J. J.; Lear, M. J. Total synthesis confirms laetirobin as a formal Diels-Alder adduct Chem.-Asian J. 2010, 5, 342-351
48. Sarmah, M. P.; Shashidhar, M. S.; Sureshan, K. M.; Gonnade, R. G.; Bhadbhade, M. M. Sulfonate protecting groups. Synthesis of O- and C-methylated inositols: d-and l -ononitol, d-and l -laminitol, mytilitol and scyllo-inositol methyl ether Tetrahedron 2005, 61, 4437-4446
49. Wallen, E. A. A.; Dahlen, K.; Grotli, M.; Luthman, K. Synthesis of 3-aminomethyl-2-aryl-8-bromo-6-chlorochromones Org. Lett. 2007, 9, 389-391
50. Poonia, N. S.; Chhabra, K.; Kumar, C.; Sharma, T. C.; Bhagwat, V. W. Coordinative role of alkali cations in organic synthesis. 2. The chalcone-flavanone system J. Org. Chem. 1977, 42, 3311-3313
51. Fridén-Saxin, M.; Pemberton, N.; da Silva Andersson, K.; Dyrager, C.; Friberg, A.; Grotli, M.; Luthman, K. Synthesis of 2-alkyl-substituted chromone derivatives using microwave irradiation J. Org. Chem. 2009, 74, 2755-2759
52. Ji, H.; Zhang, W.; Zhang, M.; Kudo, M.; Aoyama, Y.; Yoshida, Y.; Sheng, C.; Song, Y.; Yang, S.; Zhou, Y.; Lu, J.; Zhu, J. Structure-based de novo design, synthesis, and biological evaluation of non-azole inhibitors specific for lanosterol 14α-demethylase of fungi J. Med. Chem. 2003, 46, 474-485
53. Kabbe, H.-J.; Widdig, A. Synthesis and reactions of 4-chromanones Angew. Chem., Int. Ed. 1982, 21, 247-256
54. Pouget, C.; Fagnere, C.; Basly, J.-P.; Leveque, H.; Chulia, A.-J. Synthesis and structure of flavan-4-ols and 4-methoxyflavans as new potential anticancer drugs Tetrahedron 2000, 56, 6047-6052
55. Maiti, A.; Cuendet, M.; Croy, V. L.; Endringer, D. C.; Pezzuto, J. M.; Cushman, M. Synthesis and biological evaluation of abyssinone II and its analogues as aromatase inhibitors for chemoprevention of breast cancer J. Med. Chem. 2007, 50, 2799-2806
56. Vogel, S.; Heilmann, J. Synthesis, cytotoxicity, and antioxidative activity of minor prenylated chalcones from Humulus lupulus J. Nat. Prod. 2008, 71, 1237-1241
57. Jung, D. H.; Lee, Y. R.; Kim, S. H. New synthetic routes to biologically interesting geranylated flavanones and geranylated chalcones: first total synthesis of (±)-prostratol F, xanthoangelol, and (±)-lespeol Helv. Chim. Acta 2010, 93, 635-647
58. Tello, M.; Kuzuyama, T.; Heide, L.; Noel, J.; Richard, S. The ABBA family of aromatic prenyltransferases: broadening natural product diversity Cell. Mol. Life Sci. 2008, 65, 1459-1463
59. Basarab, G. S.; Hill, P. J.; Garner, C. E.; Hull, K.; Green, O.; Sherer, B. A.; Dangel, P. B.; Manchester, J. I.; Bist, S.; Hauck, S.; Zhou, F.; Uria-Nickelsen, M.; Illingworth, R.; Alm, R.; Rooney, M.; Eakin, A. E. Optimization of pyrrolamide topoisomerase II inhibitors toward identification of an antibacterial clinical candidate (AZD5099) J. Med. Chem. 2014, 57, 6060-6082
60. Nimesh, H.; Sur, S.; Sinha, D.; Yadav, P.; Anand, P.; Bajaj, P.; Virdi, J. S.; Tandon, V. Synthesis and biological evaluation of novel bisbenzimidazoles as Escherichia coli topoisomerase IA inhibitors and potential antibacterial agents J. Med. Chem. 2014, 57, 5238-5257
61. Cheng, B.; Cao, S.; Vasquez, V.; Annamalai, T.; Tamayo-Castillo, G.; Clardy, J.; Tse-Dinh, Y.-C. Identification of anziaic acid, a lichen depside from Hypotrachyna sp., as a new topoisomerase poison inhibitor PLoS One 2013, 8, e60770
62. Lin, H.; Annamalai, T.; Bansod, P.; Tse-Dinh, Y.-C.; Sun, D. Synthesis and antibacterial evaluation of anziaic acid and its analogues as topoisomerase I inhibitors MedChemComm 2013, 4, 1613-1618
63. Basarab, G. S.; Manchester, J. I.; Bist, S.; Boriack-Sjodin, P. A.; Dangel, B.; Illingworth, R.; Sherer, B. A.; Sriram, S.; Uria-Nickelsen, M.; Eakin, A. E. Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents J. Med. Chem. 2013, 56, 8712-8735
64. Plaper, A.; Golob, M.; Hafner, I.; Oblak, M.; Šolmajer, T.; Jerala, R. Characterization of quercetin binding site on DNA gyrase Biochem. Biophys. Res. Commun. 2003, 306, 530-536
65. Russo, P.; Del Bufalo, A.; Cesario, A. Flavonoids acting on DNA topoisomerases: recent advances and future perspectives in cancer therapy Curr. Med. Chem. 2012, 19, 5287-5293
66. Constantinou, A.; Mehta, R.; Runyan, C.; Rao, K.; Vaughan, A.; Moon, R. Flavonoids as DNA topoisomerase antagonists and poisons: structure-activity relationships J. Nat. Prod. 1995, 58, 217-225
67. Black, M. T.; Stachyra, T.; Platel, D.; Girard, A.-M.; Claudon, M.; Bruneau, J.-M.; Miossec, C. Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases Antimicrob. Agents Chemother. 2008, 52, 3339-3349
68. Hoshino, K.; Kitamura, A.; Morrissey, I.; Sato, K.; Kato, J.; Ikeda, H. Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition Antimicrob. Agents Chemother. 1994, 38, 2623-2627
69. Kagawa, H.; Shigematsu, A.; Ohta, S.; Harigaya, Y. Preparative monohydroxyflavanone syntheses and a protocol for gas chromatography-mass spectrometry analysis of monohydroxyflavanones Chem. Pharm. Bull. 2005, 53, 547-554
70. Kuo, S.-C.; Lee, H.-Z.; Juang, J.-P.; Lin, Y.-T.; Wu, T.-S.; Chang, J.-J.; Lednicer, D.; Paull, K. D.; Lin, C. M.; Hamel, E.; Lee, K.-H. Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4′-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agents interacting with tubulin J. Med. Chem. 1993, 36, 1146-1156
71. Lee, R. E.; Hurdle, J. G.; Liu, J.; Bruhn, D. F.; Matt, T.; Scherman, M. S.; Vaddady, P. K.; Zheng, Z.; Qi, J.; Akbergenov, R.; Das, S.; Madhura, D. B.; Rathi, C.; Trivedi, A.; Villellas, C.; Lee, R. B.; Rakesh; Waidyarachchi, S. L.; Sun, D.; McNeil, M. R.; Ainsa, J. A.; Boshoff, H. I.; Gonzalez-Juarrero, M.; Meibohm, B.; Bottger, E. C.; Lenaerts, A. J. Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux Nat. Med. 2014, 20, 152-158
72. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes: Approved Standard. Clinical and Laboratory Standards Institute (CLSI), Wayne, PA, U.S., 2003; Vol. 23, M24-A.
73. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard, 7 th ed.; Clinical and Laboratory Standards Institute (CLSI), Wayne, PA, U.S., 2006; Vol. 26, M7-A7.
74. Rakesh; Bruhn, D.; Madhura, D. B.; Maddox, M.; Lee, R. B.; Trivedi, A.; Yang, L.; Scherman, M. S.; Gilliland, J. C.; Gruppo, V.; McNeil, M. R.; Lenaerts, A. J.; Meibohm, B.; Lee, R. E. Antitubercular nitrofuran isoxazolines with improved pharmacokinetic properties Bioorg. Med. Chem. 2012, 20, 6063-6072
75. Hurdle, J. G.; O'Neill, A. J.; Chopra, I. Anti-staphylococcal activity of indolmycin, a potential topical agent for control of staphylococcal infections J. Antimicrob. Chemother. 2004, 54, 549-552
76. Cherian, P. T.; Wu, X.; Maddox, M. M.; Singh, A. P.; Lee, R. E.; Hurdle, J. G. Chemical modulation of the biological activity of reutericyclin: a membrane-active antibiotic from Lactobacillus reuteri Sci. Rep. 2014, 4, 4721 10.1038/srep04721
77. Sorokin, E. P.; Cheng, B.; Rathi, S.; Aedo, S. J.; Abrenica, M. V.; Tse-Dinh, Y.-C. Inhibition of Mg2+ binding and DNA religation by bacterial topoisomerase I via introduction of an additional positive charge into the active site region Nucleic Acids Res. 2008, 36, 4788-4796
78. Zhu, C.-X.; Tse-Dinh, Y.-C. The acidic triad conserved in type IA DNA topoisomerases is required for binding of Mg(II) and subsequent conformational change J. Biol. Chem. 2000, 275, 5318-5322
79. Peng, H.; Marians, K. J. Escherichia coli topoisomerase IV. Purification, characterization, subunit structure, and subunit interactions J. Biol. Chem. 1993, 268, 24481-24490